Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NUTX vs EVEX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NUTX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 9–1 Matrix Metrics)

NUTX Overall Winner 6-Pillar Tally: NUTX 3 – 1 EVEX (2 Tie) Matrix Metrics: NUTX 9 – 1 EVEX

As of Nov 16, 2026, Nutex Health Inc. (NUTX) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NUTX carries a Unified Composite Score of 51.7/100 (HOLD) at $167.10 (6.2x Forward P/E, 53.7% operating margin), whereas EVEX carries 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: NUTX earns the overall head-to-head edge with a stronger Unified Composite Score (51.7/100 HOLD vs. EVEX 41.3/100 SELL) and 1.78β · 86% Vol risk profile, whereas EVEX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NUTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.9); meanwhile EVEX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NUTX vs EVEX
NUTX NASDAQ Head-to-Head Winner
Nutex Health Inc. Common Stock
Services-Business Services, Nec
$167.10
-3.78% 1D
Market Cap $1.2B
TTM Revenue $797M
Forward P/E 6.2x
Beta / 30D Vol 1.78β · 86% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 32.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.9 · SMA20: $194.11 · SMA50: $201.84
EVEX NYSE
Eve Holding, Inc.
Aircraft
$1.70
+2.41% 1D
Market Cap $597.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.71β · 96% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 20.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 43
RSI-14: 42.8 · SMA20: $1.68 · SMA50: $1.81

6-Pillar Scorecard Institutional Category Breakdown (NUTX 3 – 1 EVEX)

Columns: Metric · NUTX · EVEX
1. Valuation Multiples NUTX
Forward P/E 6.2x N/M
Trailing P/E 7.5x N/M
PEG Ratio N/M N/M
EV / Revenue 1.7x N/M
2. Growth & Scale EVEX
Revenue Growth (YoY) -18.7% +0.0%
Earnings Growth (YoY) -26.4% +0.0%
TTM Revenue (USD) $797M N/A
Market Cap $1.2B $597.7M
3. Profitability & Quality NUTX
Gross Margin 51.3% N/A
Operating Margin 53.7% 0.0%
Net Profit Margin 20.7% 0.0%
Return on Equity (ROE) 47.6% -300.9%
4. Balance Sheet & Cash Flow NUTX
Cash Generation (TTM) $274M N/A
Cash Flow Margin 34.4% N/A
Net Cash / Leverage $142M Net Debt (0.88x D/E) -300.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 72.3% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Aerospace & Defense Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NUTX (9) vs EVEX (1)
Institutional Metric NUTX EVEX Criterion Row Edge
Market Capitalization
Scale
$1.2B $597.7M Larger Scale NUTX
Trailing P/E Ratio
Valuation
7.5x N/M Lower Multiple NUTX
Forward P/E Ratio
Valuation
6.2x N/M Lower Multiple NUTX
Revenue Growth (YoY)
Growth
-18.7% +0.0% Higher Growth EVEX
Operating Margin (TTM)
Profitability
53.7% 0.0% Higher Margin NUTX
Net Profit Margin
Profitability
20.7% 0.0% Higher Margin NUTX
Return on Equity (ROE)
Capital Efficiency
47.6% -300.9% Higher ROE NUTX
52-Week Range Position
Momentum
58% ($84–$226) 8% ($1–$5) Stronger Trend NUTX
Beta / 30D Volatility
Risk Regime
1.78β · 86% Vol 2.71β · 96% Vol Lower Realized Risk NUTX
Unified Institutional Score
Composite Signal
51.7 / 100 (HOLD) 41.3 / 100 (SELL) Higher Composite NUTX
Trailing 12M Revenue (USD)
Operating Scale
$797M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
51.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$274M ($142M Net Debt (0.88x D/E)) N/A (-300.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVEX +15.15 pp
NUTX: -10.21% · EVEX: +4.94%
3M Horizon NUTX +24.89 pp
NUTX: -10.96% · EVEX: -35.85%
6M Horizon NUTX +74.97 pp
NUTX: +34.0% · EVEX: -40.97%
1Y Horizon NUTX +112.7 pp
NUTX: +53.57% · EVEX: -59.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NUTX vs EVEX. Trailing 12-month operating profitability (NUTX 53.7% vs EVEX 0.0%) and valuation multiples (NUTX 6.2x vs EVEX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NUTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797M
Gross Margin51.3%
Op. Margin53.7%
ROE / Fwd P/E47.6% · 6.2x
EVEX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-300.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NUTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NUTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVEX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 72.3%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVEX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NUTX Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.2B market capitalization and 53.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVEX Moat Profile Cyclical / Execution-Driven Positioning
Aerospace & Defense Operator
Competes within the Aerospace & Defense value chain with $597.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NUTX vs EVEX Key Questions & Quantitative Answers

As of Nov 16, 2026, Nutex Health Inc. (NUTX) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NUTX carries a Unified Composite Score of 51.7/100 (HOLD) at $167.10 (6.2x Forward P/E, 53.7% operating margin), whereas EVEX carries 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NUTX earns the overall head-to-head edge with a stronger Unified Composite Score (51.7/100 HOLD vs. EVEX 41.3/100 SELL) and 1.78β · 86% Vol risk profile, whereas EVEX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NUTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.9); meanwhile EVEX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EVEX leads the Growth & Scale pillar: NUTX posts -18.7% YoY revenue growth and -26.4% YoY earnings growth on $797M TTM revenue (51.3% gross margin, 53.7% operating margin), compared with EVEX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NUTX generates $797M in USD-normalized revenue versus N/A for EVEX. In operating R&D and SG&A reinvestment, NUTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVEX.

NUTX screens cheaper on headline valuation multiples. NUTX trades at 6.2x Forward P/E, 7.5x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (34.4% FCF margin), whereas EVEX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUTX (47.6% ROE) versus EVEX (-300.9% ROE) capital efficiency.

In options market volatility and institutional positioning, NUTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.78β · 86% Vol realized risk). By comparison, EVEX carries 72.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.71β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.